Navigation Links
Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Date:4/1/2009

Arginine vasopressin (AVP) receptor antagonist now available in new premixed formulation

DEERFIELD, Ill., April 1 /PRNewswire/ -- Astellas Pharma US, Inc. today announced the commercial availability of Vaprisol(R) (conivaptan hydrochloride injection) Premixed in 5% Dextrose, a new premixed formulation. Discovered and developed by Astellas, Vaprisol, an arginine vasopressin (AVP) receptor antagonist, is the first and only approved drug indicated for the treatment of both euvolemic and hypervolemic hyponatremia in hospitalized patients.(1) Hyponatremia is a potentially life-threatening condition that occurs when the body's blood sodium level falls significantly below normal.(2) Vaprisol Premixed was approved by the U.S. Food and Drug Administration in October 2008.

The 100mL, single-use premixed formulation of Vaprisol comes in a plastic INTRAVIA(R) Container, a product of Baxter Healthcare Corporation, containing 20mg of conivaptan hydrochloride in 5% dextrose solution. Lactic acid, USP is added for pH adjustment to pH 3.4 to 3.8. The new formulation will make preparation easier for health care providers, as it requires no measuring or mixing.(1) Additionally, it has an expiration date of 24 months, six months longer than the original ampule formulation.(3)

"It is imperative to promptly address hyponatremia in emergency and hospital settings," said Dr. Joseph Verbalis, M.D., Professor of Medicine and Physiology at Georgetown University. "Vaprisol Premixed in 5% Dextrose is a convenient option for quickly preparing treatment for hyponatremia patients."

Hyponatremia is present in approximately 28 percent of patients upon admission into acute hospital care, and another 14 percent acquire the condition while in acute care.(4) Severe cases are medical emergencies that can result in swelling of the brain, respiratory arrest, catastrophic brain damage and death.(5)

In the treatment of hyponatremia associated with congestive heart failure, Vaprisol is indicated only for those patients for whom the expected benefit of raising serum sodium outweighs the increased risk of adverse events. Vaprisol is contraindicated in patients with hypovolemic hyponatremia.(1)

About Hyponatremia

Hyponatremia, a condition of low serum sodium concentration, often results from elevated levels of the hormone arginine vasopressin (AVP), which regulates water and salt balance in the body. It is the most common electrolyte disorder in clinical medicine and one of the most difficult to treat.(5) Syndrome of inappropriate antidiuretic hormone (SIADH), advanced kidney failure, hypothyroidism(2) and cancer(6) are common causes of hyponatremia. Dilutional hyponatremia, which includes euvolemic and hypervolemic hyponatremia, is the most common form of the condition, and occurs when retained water dilutes serum sodium content.(5) Patients with hyponatremia are classified as hypervolemic if swelling of body tissues (edema) is present(7) or euvolemic if there is an increase in total body water content without edema.(5)

About Vaprisol

Discovered and developed by Astellas Pharma Inc., headquartered in Tokyo, Japan, Vaprisol is a drug that blocks the activity of AVP, resulting in increased urine output without loss of valuable electrolytes such as sodium and potassium. This effect, known as "aquaresis," helps to increase serum sodium levels in patients with hyponatremia. Vaprisol is the first AVP receptor antagonist with a demonstrated safety profile and that effectively promotes aquaresis in order to help restore salt and water balance in patients with euvolemic and hypervolemic hyponatremia.(1)

Vaprisol is indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. Vaprisol is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. In addition, coadministration of Vaprisol with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritanovir, and indinavir, is contraindicated. Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products. Serum sodium, volume, and neurological status must be monitored frequently because Vaprisol potentially can cause overly rapid correction of sodium leading to serious sequelae. The use of Vaprisol in patients with hepatic impairment (including ascites, cirrhosis, or portal hypertension) or renal impairment has not been systematically evaluated. Use caution when administering Vaprisol to these patients. The most common adverse reactions reported were infusion site reactions (incidence of 73% and 63% for 20 mg/day and 40 mg/day respectively) which were also the most common type of adverse reaction leading to discontinuation of Vaprisol. Discontinuations from treatment due to infusion site reactions were more common among Vaprisol-treated patients (3%) than among placebo-treated patients (0%). Other common adverse reactions were headaches (8%, 10%), hypokalemia (22%, 10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for Vaprisol 20mg/day and 40mg/day, respectively.(1) For full prescribing information, please visit www.Vaprisol.com.

About Astellas

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a US affiliate of Tokyo-based Astellas Pharma Inc., Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global pharmaceutical company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. For more information about Astellas Pharma US, Inc., please visit our website at www.astellas.com/us.

INTRAVIA is a registered trademark of Baxter International Inc.

References:

  1. Vaprisol [package insert]. Deerfield, IL: Astellas Pharma US, Inc.; 2008.
  2. Lien YH, Shapiro JI. Hyponatremia: Clinical Diagnosis and Management. Am J Med. 2007;120(8):652-658
  3. Data on file. Astellas.
  4. Upadhyay A, Jaber BL, Madias NE. Incidence and Prevalence of Hyponatremia. Am J Med. 2006; 119 (7A): S31-S35.
  5. Ghali JK. Mechanisms, Risks and New Treatment Options for Hyponatremia. Cardiology. 2008;111:147-157.
  6. Onitilo AA, Ko E, Doi SA. Tumor-related Hyponatremia. Clin Med Res. 2007;5(4): 228-237.
  7. Goh KP. Management of Hyponatremia. Am Fam Physician. 2004;69(10) 2387-2394.


'/>"/>
SOURCE Astellas Pharma US, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. FDA Approves Additional Indication for Astellas MYCAMINE(R)
3. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
4. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
5. UPMC Health Plan Launches New Personal Health Record
6. HealthInsuranceFinders.com Launches Video Contest for Young Directors
7. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
8. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
9. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
10. Mannatech Launches Phase One of New Sales and Training Tools
11. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line ... in Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than ... by government agencies, including NASA. , In 2012, NASA strategically set up 17 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks ... Amica Insurance is sharing tips to make sure your family and vehicle are ... National Safety Council, there may be 439 deaths and an additional 50,500 serious injuries ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at ... daily practices, arts & crafts, discussions, and games all geared towards enhancing your ... have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
(Date:5/26/2016)... ... May 26, 2016 , ... Workrite ... sales leadership and to further develop their rapidly expanding portfolio of customer and ... with a concentration in Marketing and an M.B.A. with concentration in management from ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
Breaking Medicine Technology: